Compare H.U. Group Holdings, Inc. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a -28.61% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Operating profit has grown by an annual rate -28.61% of over the last 5 years
3
The company has declared Positive results for the last 4 consecutive quarters
4
With ROCE of 3.12%, it has a very attractive valuation with a 1.32 Enterprise value to Capital Employed
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 192,255 Million (Small Cap)
27.00
NA
0.00%
0.11
5.03%
1.40
Revenue and Profits:
Net Sales:
62,590 Million
(Quarterly Results - Jun 2026)
Net Profit:
1,547 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.57%
0%
12.57%
6 Months
15.53%
0%
15.53%
1 Year
2.19%
0%
2.19%
2 Years
33.33%
0%
33.33%
3 Years
35.54%
0%
35.54%
4 Years
34.88%
0%
34.88%
5 Years
13.39%
0%
13.39%
H.U. Group Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.09%
EBIT Growth (5y)
-28.61%
EBIT to Interest (avg)
38.50
Debt to EBITDA (avg)
0.97
Net Debt to Equity (avg)
0.25
Sales to Capital Employed (avg)
1.16
Tax Ratio
21.87%
Dividend Payout Ratio
102.87%
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
10.14%
ROE (avg)
10.97%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
1.36
EV to EBIT
42.30
EV to EBITDA
7.62
EV to Capital Employed
1.32
EV to Sales
0.82
PEG Ratio
0.30
Dividend Yield
NA
ROCE (Latest)
3.12%
ROE (Latest)
5.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Bullish
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.12%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
62,590.00
60,633.00
3.23%
Operating Profit (PBDIT) excl Other Income
7,166.00
5,795.00
23.66%
Interest
159.00
167.00
-4.79%
Exceptional Items
-97.00
-230.00
57.83%
Consolidate Net Profit
1,547.00
1,188.00
30.22%
Operating Profit Margin (Excl OI)
33.60%
9.90%
2.37%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 3.23% vs -2.73% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 30.22% vs -77.89% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
247,362.00
243,025.00
1.78%
Operating Profit (PBDIT) excl Other Income
26,537.00
23,092.00
14.92%
Interest
686.00
591.00
16.07%
Exceptional Items
-73.00
-360.00
79.72%
Consolidate Net Profit
6,704.00
2,731.00
145.48%
Operating Profit Margin (Excl OI)
19.30%
9.70%
0.96%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 1.78% vs 2.56% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 145.48% vs 136.16% in Mar 2025
About H.U. Group Holdings, Inc. 
H.U. Group Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






